Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
NEW YORK, Feb. 22, 2013 /PRNewswire/ -- Dr Wei William Cao, PhD, BM, President of Cellular Biomedicine Group presented a keynote address at the 8th annual New York Stem Cell Summit on February 19, 2013. Dr Cao discussed the current government regulations and support of cellular medicine research and development in China.
The New York Stem Cell Summit featured more than 30 of the world's leaders in the stem cell industry, bringing the future of this dynamic industry to life for investors, industry, practitioners, and analysts. The presentations and networking provided insight into investment opportunities in the stem cell marketplace, groundbreaking stem cell products that physicians use today, and the growing market potential.
Dr Cao served as Technical Manager for Bayer Diagnostics Asia Pacific region, General Manager of GenoMultix Ltd., President of Wuxi New District Hospital, and China General Manager of Affymetrix, a world leader in genetic analysis industry. Dr Cao has extensive research experience in immunopharmacology at Harvard Medical School and Stanford Medical School. He holds a Guest Professorship at the Department of Histology and Embryology of Fudan University Medical School, Shanghai China. Dr Cao earned a Bachelor's degree in Medicine from Fudan University Medical School, Shanghai China, and PhD degree in immunopharmacology from Medical College of Virginia, Richmond Virginia. He is an inventor of 24 patents in the field of genetic analysis and stem cell technology, especially adipose derived stem cell preparation and its disease treatment applications.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Ltd. develops proprietary cell therapies for the treatment of certain degenerative diseases. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue," or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company has no obligation to update these forward-looking statements.
ProActive Capital Group
Director of Corporate Communications
(+86) 21 54069990
SOURCE Cellular Biomedicine Group